Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer

Jason O'Byrne is leaving the company to pursue another opportunity and will stay until August 3 to support a smooth handover. Vir Biotechnology has also started a search for a new Chief Financial Officer.

Brent Sabatini has been Senior Vice President, and Chief Accounting Officer at Vir Biotechnology since February 2023. He has more than 20 years of experience in finance and accounting, and previously served as Head of Finance at Capsida Biotherapeutics.

Read More:Merit Receives Minority Investment from SEMCAP Beauty & Wellness

Before that, he spent 17 years at Amgen, where he held leadership roles in accounting, tax, and financial planning. Sabatini is a Certified Public Accountant and holds a bachelor's degree in Accountancy from California State University, Northridge, and an MBA from the University of Michigan's Ross School of Business.

"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish a strong cash position for the Company,” said Marianne De Backer, Chief Executive Officer of Vir Biotechnology. “The Board and I are confident that our financial organization is in good hands as we manage through this transition."

About Vir Biotechnology

Founded in 2016, Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases, and cancer. Its pipeline includes treatments for chronic hepatitis delta, and several PRO-XTEN® T-cell engager programs for solid tumors.

Read More:California-Based Prosper Medical Scores $16M in Funding Round